Vetter Pharma, officially known as Vetter Pharma-Fertigung GmbH & Co. KG, is a leading global provider of aseptic filling and packaging services for the pharmaceutical and biotechnology industries. Headquartered in Ravensburg, Germany, the company operates extensively across Europe, North America, and Asia, catering to a diverse clientele. Founded in 1950, Vetter Pharma has achieved significant milestones, including the development of innovative delivery systems and a commitment to high-quality standards. The company specialises in prefilled syringes, vials, and cartridges, distinguished by their precision and reliability. Vetter's strong market position is underscored by its reputation for excellence and a robust portfolio of services that support drug development and commercialisation. With a focus on customer-centric solutions, Vetter Pharma continues to be a trusted partner in the evolving landscape of healthcare.
How does Vetter Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Vetter Pharma's score of 42 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Vetter Pharma reported total carbon emissions of approximately 16,986,000 kg CO2e, with Scope 1 emissions accounting for about 16,044,200 kg CO2e and Scope 3 emissions at approximately 3,778,000 kg CO2e. The company has demonstrated a commitment to reducing its carbon footprint, aiming for a significant reduction of 58.8% in Scope 1 and 2 emissions by 2030, using 2021 as the base year. This target is currently being validated by the Science Based Targets initiative (SBTi). In 2023, Vetter Pharma's emissions were approximately 17,852,000 kg CO2e for Scope 1 and about 3,613,000 kg CO2e for Scope 3. The company has set an annual reduction target of 4.2% for both Scope 1 and 2 emissions, which is part of its broader strategy to achieve net zero emissions by 2050. Vetter Pharma's emissions data is sourced directly from its own reporting, with no cascaded data from parent companies. The company is actively working towards its climate commitments, aligning with industry standards to mitigate its environmental impact.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 17,770,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | - | - |
| Scope 3 | - | - | 0,000,000 | 0,000,000 | 0,000,000 |
Vetter Pharma's Scope 3 emissions, which increased by 5% last year and increased by approximately 32% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Waste Generated in Operations" being the largest emissions source at 77% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Vetter Pharma has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


Common questions about Vetter Pharma's sustainability data and climate commitments